Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2
The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.34 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | CRAT | P43155 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | CPT1A | P50416 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Choline SCHEMBL16684869 | 0.98 | LMNA (0.48) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL16684846 | 0.89 | MEN1 (0.57) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL780251 | 0.86 | LMNA (0.55) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL16684870 | 0.86 | MEN1 (0.55) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL4184744 | 0.86 | CYP3A4 (0.62) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL21380519 | 0.86 | LMNA (0.60) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL4184740 | 0.84 | CYP3A4 (0.65) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL16684873 | 0.84 | LMNA (0.57) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL10630113 | 0.84 | LMNA (0.63) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL119826 | 0.84 | LMNA (0.63) | LMNAMEN1KMT2ACYP3A4SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114044852-B | Polymerizable eutectic solvent, conductive elastomer and preparation method of conductive elastomer | 江南大学 | 2022-11-22 | — | — | CN | claimed |
| CN-114044852-A | Polymerizable eutectic solvent, conductive elastomer and preparation method thereof | 江南大学 | 2022-02-15 | — | — | CN | claimed |
| US-20260034075-A1 | CHOLINE CARBOXYLIC ACID BASED IONIC LIQUIDS AS ANTIMICROBIAL AGENTS | UNIV MISSISSIPPI (US) | 2026-02-05 | — | — | US | disclosed |
| US-12440438-B2 | Method of remotely controlling pain | Novilla Pharmaceuticals, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3503927-B1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | UNIV CALIFORNIA (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240156964-A1 | IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY | THE ARIZONA BOARD OF REGENTS | 2024-05-16 | — | — | US | disclosed |
| WO-2024044526-A1 | RED BLOOD CELL-HITCHHIKING IONIC LIQUID COATED NANOPARTICLES FOR CROSSING THE BLOOD BRAIN BARRIER | UNIVERSITY OF MISSISSIPPI (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024030844-A1 | CHOLINE CARBOXYLIC ACID BASED IONIC LIQUIDS AS ANTIMICROBIAL AGENTS | UNIVERSITY OF MISSISSIPPI (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11786597-B2 | Ionic liquids for transdermal drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230310528-A1 | DEEP EUTECTIC SOLVENT INCLUDING ONE OR MORE ACTIVE PHARMACEUTICAL INGREDIENTS DERIVED FROM MUSHROOMS | OPTIMI HEALTH CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| CN-109789216-B | Topical skin treatment formulations based on ionic species | 加利福尼亚大学董事会 | 2023-05-23 | — | — | CN | disclosed |
| EP-3503927-A1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | The Regents of the University of California (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190192661-A1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-06-27 | — | — | US | disclosed |
| EP-2436736-B1 | ORGANOSILOXANE RESIN COMPOSITION AND LAMINATE COMPRISING SAME | TEIJIN CHEMICALS LTD (JP) | 2018-03-28 | — | — | EP | disclosed |
| WO-2018044920-A1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20160263225-A1 | IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY | THE ARIZONA BOARD OF REGENTS | 2016-09-15 | — | — | US | disclosed |
| EP-3062819-A2 | IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY | The Regents of The University of California (US) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015066647-A9 | IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015066647-A2 | IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20120070676-A1 | ORGANOSILOXANE RESIN COMPOSITION AND LAMINATE COMPRISING THE SAME | TEIJIN CHEMICALS, LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192661-A1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | CUTA, KRT18, SLC38A7 | LMNA 984/4885MEN1 3637/4885KMT2A 4681/4885 |
| US-20260034075-A1 | CHOLINE CARBOXYLIC ACID BASED IONIC LIQUIDS AS ANTIMICROBIAL AGENTS | ELOVL3, L3MBTL3, ELOVL6 | LMNA 2830/4885MEN1 1949/4885KMT2A 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.